 |
|
|
| |
UTILIZATION OF ELBASVIR / GRAZOPREVIR (EBR/GZR) AND ADOPTION OF RESISTANCE ASSOCIATED SUBSTITUTIONS (RAS) TESTING IN REAL-WORLD TREATMENT OF HCV GENOTYPE 1 (GT1) INFECTION:
RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R)
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Holger Hinrichsen 1, Hartwig Klinker 2, Albrecht Stoehr 3, Christine John 4, Renate Heyne 5, Gerd Klausen 6, Karl-Georg Simon 7, Markus Cornberg 8, Manfred Kuhn 9, Uwe Naumann 10, Manfred Bilzer 11, Karen Bayer 12, Vanessa Witte 12, Stefan Zeuzem 13
1 Gastroenterology-Hepatology Center Kiel, Kiel; 2 University Hospital Wuerzburg, Wuerzburg; 3 ifi - Institute for Interdisciplinary Medicine, Study Centre St. Georg, Hamburg; 4 Private Practice of Internal Medicine, Berlin; 5 Leberzentrum am Checkpoint, Berlin; 6 Schwerpunktpraxis Berlin-Mitte, Berlin; 7 MVZ Dres. Eisenbach, Simon, Schwarz GbR, Leverkusen; 8 Hannover Medical School, Hannover; 9 Practice of Gastroenterology, Kassel; 10 Praxiszentrum Kaiserdamm, Berlin; 11 Bilzer Consulting, Munich; 12 MSD Sharp & Dohme GmbH, Haar; 13 Johann Wolfgang Goethe University, Frankfurt
|
| |
|
|
|
|
|
